In the case of positive sterility results, health care provider(s) will be contacted.To create a favorable environment for healing, concomitant pathologies that include meniscal pathology, cruciate ligament instability and joint misalignment, must be addressed prior to or concurrent with the implantation of MACI.Local treatment guidelines regarding the use of thromboprophylaxis and antibiotic prophylaxis around orthopaedic surgery should be followed. If you suffer from cartilage damage in your knees, we invite you to call us at 703.272.5000 to schedule an appointment with Dr. David Goodwin , here at Arthritis & Sports. Consult your doctor if you have cancer in the area of the cartilage biopsy or implant as the safety of MACI is not known in those cases.Conditions that existed before your surgery, including meniscus tears, joint or ligament instability, or alignment problems should be evaluated and treated before or at the same time as the MACI implant.MACI has not been studied in patients younger than 18 or over 55 years of age.Common side effects include joint pain, tendonitis, back pain, joint swelling, and joint effusion.More serious side effects include joint pain, cartilage or meniscus injury, treatment failure, and osteoarthritis.This site is intended for United States residents only.©2020 Vericel Corporation. MACI is also contraindicated for patients with severe osteoarthritis of the knee, inflammatory arthritis, inflammatory joint disease, or uncorrected congenital blood coagulation disorders. ... Called Maci, it puts the cells inside a dissolvable scaffold -- placed inside the knee -- that’s designed to grow new cartilage. It is not known whether MACI is safe or effective in patients over the age of 55 years. MACI is contraindicated in patients with a known history of hypersensitivity to gentamicin, other aminoglycosides, or products of porcine or bovine origin. Many case series (level 4 evidence) are available reporting improvement of pain and function after this procedure in short- and medium-term follow-up[22,39,48,49,55-60]. PP.US.MAC.0836 v3.0 MACI is contraindicated in patients with a known history of hypersensitivity to gentamicin, other aminoglycosides, or products of porcine or bovine origin. We prospectively followed 153 patients (155 knees) for up to 11 years after treatment with ACI for early-stage osteoarthritis. MACI is the first FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient’s own knee. Relevant clinical studies are summarized in table table1. MACI Procedure.

PP.US.MAC.0835 v4.0MACI is contraindicated in patients with a known history of hypersensitivity to gentamicin, other aminoglycosides, or products of porcine or bovine origin. Expansion of present malignant or dysplastic cells during the culturing process or implantation is possible.Patients undergoing procedures associated with MACI are not routinely tested for transmissible infectious diseases. For more information about what Vericel collects and how we use it, visit our Privacy Policy.MACI showed statistically significantly greater improvement over microfracture for The most frequently occurring adverse reactions (≥5%) reported for MACI were arthralgia, tendonitis, back pain, joint swelling, and joint effusion.Serious adverse reactions reported for MACI were arthralgia, cartilage injury, meniscus injury, treatment failure, and osteoarthritis.With its unique cell-seeded biocompatible membrane, MACI provides a suture-free delivery method for autologous cultured chondrocytes.1. MACI is also contraindicated for patients with severe osteoarthritis of the knee, inflammatory arthritis, inflammatory joint disease, or uncorrected congenital blood coagulation disorders. Patient pain and function was assessed using WOMAC, modified Cincinnati, SF-36, Knee Society score, and a satisfaction questionnaire.